AbCellera Biologics
AbCellera Biologics Inc is a Canadian biotechnology company providing an AI-powered antibody discovery and development platform. The company searches, decodes, and analyzes natural immune systems to discover monoclonal antibody candidates for therapeutic applications. Main revenue drivers consist of research collaboration fees, milestone payments, licensing fees, and potential downstream product royalties. AbCellera serves global pharmaceutical enterprises, mid-sized biotechnology companies, and academic research institutions across North America and Europe. The company occupies a prominent market position as an technology engine for rapid therapeutic antibody discovery. Headquartered in Vancouver, Canada, AbCellera Biologics Inc is listed on the Nasdaq Stock Market.
6 of the funds FundTelligence covers report a position in AbCellera Biologics.
- Legal name
- AbCellera Biologics Inc
- Sector
- Health Care
- Country
- Canada
- Funds holding it
- 6
- Exposure themes
- Autoimmune diseases, Biotechnology platforms, Treatment, Women's Health
Funds holding AbCellera Biologics
- DNB Fund Disruptive Opportunities — DNB · 1.85 % (full portfolio disclosed, September 2026)
- DNB Fund Women's Health — DNB · 1.17 % (full portfolio disclosed, August 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.7 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.27 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.25 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)